PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE
PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including PANCREAZE. Available dosage form: capsule, delayed release.
Drug Details
- Generic Name
- PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE
- Brand Names
- PANCREAZE
- Application Number
- BLA022523
- Sponsor
- VIVUS LLC
- NDC Codes
- 6
- Dosage Forms
- CAPSULE, DELAYED RELEASE
- Routes
- ORAL
- Active Ingredients
- PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE
Indications and Usage
1 INDICATIONS AND USAGE PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )